Skip to main content
. 2021 May 22;34(5):511–520. doi: 10.1093/ajh/hpaa184

Table 2.

Blood pressure characteristics of SPRINT (Systolic Blood Pressure Intervention Trial) participants in the ambulatory blood pressure ancillary study by orthostatic hypotension history at the 6-, 12-, or 24-month SPRINT study visit, mean (SD) or %

Variable Total Orthostatic hypotension at least once during 6-, 12-, and 24-month visits No occurrence of orthostatic hypotension
N = 897 N = 128 N = 769
Clinic SBP, mm Hg (27-mo) 127.6 (15.6) 129.2 (17.1) 127.4 (15.3)
Clinic DBP, mm Hg (27-mo) 69.7 (12.0) 69.7 (13.1) 69.7 (11.8)
White coat effect, % 8.3 14.8 7.2
Dipping status, %
 Extreme dipper 10.3 3.1 11.4
 Dipper 35.3 28.1 36.5
 Nondipper 38.8 43.8 38.0
 Reverse dipper 15.6 25.0 14.0
BP phenotypes, %
 White coat hypertension 5.7 10.2 4.9
 Masked hypertension 26.2 25.0 26.4
 Controlled hypertension 51.1 48.4 51.6
 Sustained hypertension 17.0 16.4 17.1
N antihypertensive medications (27-mo) 2.3 (1.3) 2.4 (1.3) 2.3 (1.3)

24-mo, data collected at 24-month annual visit; 27-mo, data collected at 27-month study visit. Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; N antihypertensive medication, number of antihypertensive medications; SBP, systolic blood pressure. Participant BP phenotypes were defined as follows: (i) white-coat hypertension (clinic BP ≥140/90 mm Hg and daytime ambulatory BP <135/85 mm Hg), (ii) masked hypertension (clinic BP <140/90 mm Hg and daytime ambulatory BP ≥135/85 mm Hg), (iii) controlled hypertension (clinic BP <140/90 mm Hg and daytime ambulatory BP <135/85 mm Hg), and (iv) sustained hypertension (clinic BP ≥140/90 mm Hg and daytime ambulatory BP ≥135/85 mm Hg).